Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
Phase 2
150
about 23 years
18+
1 site in TX
What this study is about
This trial is testing the effects of cladribine and rituximab, a treatment combination, on patients with hairy cell leukemia. Cladribine is a drug that stops cancer cells from growing or spreading, while rituximab helps the immune system fight cancer. The goal is to see how well this combination works in treating hairy cell leukemia.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Laboratory Biomarker Analysis
- 2.Receive Rituximab
- 3.Take Cladribine
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cladribine, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them)
injection, intravenous, infusion
Primary: Efficacy of rituximab on prolongation of event-free survival, Efficacy of rituximab on prolongation of overall survival, Monitoring the related toxicity for the therapy Grade 3-4
Oncology